NRD
URGN icon

Nebula Research & Development’s UroGen Pharma URGN Stock Holding History

Nebula Research & Development’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,843
Closed -$162K – 827
2025
Q2 		$162K Buy
+11,843
New +$114K 0.01% 905

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Nebula Research & Development's URGN Position: Q3 2025 in Review

Nebula Research & Development sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 11,843 shares — an estimated $162K sold.

Nebula Research & Development first reported a position in URGN in Q2 2025 and held it in 1 quarter. The position peaked at $162K in Q2 2025. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • Nebula Research & Development reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 11,843 UroGen Pharma shares in Q3 2025, an estimated $162K.
  • Nebula Research & Development first reported a position in UroGen Pharma in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's UroGen Pharma position peaked at $162K in Q2 2025.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.